Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
HQ
Founded
2014
Lyzz Capital is a global healthcare-dedicated venture capital and private equity firm, actively investing from funds totaling over $600 million. The firm focuses on both USD and RMB investments, targeting various stages of healthcare companies. Lyzz Capital's typical investment rounds include Series A, B, and D, demonstrating their commitment to supporting companies at different growth phases.
The firm's team comprises highly experienced investment and operating professionals from leading pharmaceutical/biotech companies and Wall Street firms, bringing strong scientific and medical expertise. Notable portfolio companies include Jumpcode Genomics, Neurelis, Onchilles Pharma, OncoMyx Therapeutics, Viron, and Wugen. Lyzz Capital's decade-long collaborative approach and industry knowledge position them as valuable partners for healthcare startups.
Also Known As
Lyzz Capital
Operating Status
Active
Lyzz Capital Address
San Diego,
California
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts